Nabiximols, an oromucosal spray of a complete cannabis plant extract with a 1:one ratio of THC to cannabidiol (CBD), was at first licensed and authorised in Europe, the uk, and Canada to the remedy of agony and spasticity related to many sclerosis (GW Prescribed drugs, 2016; Pertwee, 2012), but it really carries on to bear evaluation in Phase III m